kawasaki disease recurrence, Kawasaki disease recurrence in the COVID-19 era: a systematic review of the literature | Italian Journal of | Full Text, Clarithromycin Plus Intravenous Immunoglobulin Therapy Can Reduce the Relapse Rate of Kawasaki Disease: A Phase 2, Open‐Label, Randomized Control | Journal of the American Heart Association

Recurrent Kawasaki disease and cardiac complications: surveys in | Archives of Disease in Childhood

FEVER AND BACTERIURIA REFRACTORY KAWASAKI DISEASE WITH CORONARY ANEURYSM: RECURRENCE URINARY TRACT INFECTION? | Journal of the American of Cardiology

Disease

Kawasaki disease for Gupta A, Singh S - Indian Dermatol Online

Clarithromycin Plus Intravenous Immunoglobulin Therapy Can Reduce the Relapse Rate of Kawasaki Disease: A Phase 2, Open‐Label, Randomized Control | Journal of the American Heart Association

Revised recommendations of the Society of Pediatrics the general management of Kawasaki disease | Italian Journal of | Full

Frontiers | Kawasaki Disease Pediatrics

The of early intravenous immunoglobulin for Kawasaki disease: The 22nd survey in Japan - International Journal of Cardiology

Kawasaki Disease Outcomes and Response to Therapy in a Multiethnic Community: A - The Journal

Treatment, and Management of Kawasaki Disease: A Scientific for Health Professionals From the American Heart Association | Circulation

Diagnosis, Treatment, and Long-Term Management Kawasaki | Circulation

Frontiers | Increased Incidence Kawasaki Disease in Taiwan in Recent Years: A 15 Nationwide Population-Based Study | Pediatrics

Recurrent Kawasaki | British Dental Journal

Defining the first intravenous immunoglobulin unresponsiveness in non-Asian with Kawasaki disease | Scientific Reports

Kawasaki guidelines of Italian Society of Pediatrics, II - treatment of resistant forms and cardiovascular complications, follow-up, lifestyle prevention of cardiovascular risks | Italian Journal of Pediatrics | Full Text

RACGP - Kawasaki – the of recognition and early

| The Epidemiology and Pathogenesis of Kawasaki Disease | Pediatrics

Efficacy of primary with immunoglobulin plus ciclosporin for prevention of coronary artery abnormalities in patients with Kawasaki disease predicted to be at increased risk of non-response to intravenous immunoglobulin (KAICA): a

Practice Guidelines : Kawasaki disease

Combination therapy reduces for abnormalities, treatment failure Kawasaki

Cumulative recurrence rates of Kawasaki calculated by different... | Download Scientific Diagram

Kawasaki disease recurrence in the COVID-19 era: a systematic review of the literature | Italian Journal of | Full Text

Risk of Acquiring Kawasaki Disease: A Nationwide Birth Cohort Database Study The of Pediatrics

Kawasaki A Review Journal of Pediatric Health Care

Diagnosis, Treatment, and Long-Term Management Kawasaki | Circulation

Children Free Full-Text | Major Complication Following Kawasaki Disease in an Infant—The Development Apical Infarction and Aneurysm | HTML

Environmental epidemiology of Kawasaki disease: disease pathogenesis and global distribution

Refractory Kawasaki disease UpToDate